Deutsche Bank Reiterates Buy on Achillion Pharmaceuticals (ACHN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
FBR Capital Says Achillion's (ACHN) Nuc Has Greatest Potency Versus Gilead's (GILD) Sovaldi in the GT3 HCV Subtype
October 1, 2014 1:06 PM EDTFBR Capital analyst Andrew Beren offered some positive comments on Achillion Pharmaceuticals (NASDAQ: ACHN) moments ago noting abstracts from AASLD showcasing preclinical data for Achillions ACH-3422 suggest that the NS5B nucleotide (nuc) inhibitor may have the greatest potency versus Gileads Sovaldi in the GT3 HCV subtype (7-fold as potent).
"Importantly, we view the GT3 subtype as the genotype with the greatest unmet medical need currently, as it requires extended duration... More
Achillion Pharma (ACHN), Novavax (NVAX) Lower as Johnson & Johnson Acquires Alios BioPharm.
September 30, 2014 10:14 AM EDTAchillion Pharma (NASDAQ: ACHN) is down 4% early amid investors concern after Johnson & Johnson (NYSE: JNJ) announced a definitive agreement to acquire privately-held Alios BioPharma, not Achillion or Novavax (NASDAQ:... More
